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Ehlers-Danlos syndrome (EDS) type I (the classical variety) is a dominantly inherited, genetically heterogeneous
connective-tissue disorder. Mutations in the COL5A1 and COL5A2 genes, which encode type V collagen, have
been identified in several individuals. Most mutations affect either the triple-helical domain of the protein or the
expression of one COL5A1 allele. We identified a novel splice-acceptor mutation (IVS4-2ArG) in the N-propeptide-
encoding region of COL5A1, in one patient with EDS type I. The outcome of this mutation was complex: In the
major product, both exons 5 and 6 were skipped; other products included a small amount in which only exon 5
was skipped and an even smaller amount in which cryptic acceptor sites within exon 5 were used. All products
were in frame. Pro-a1(V) chains with abnormal N-propeptides were secreted andwere incorporated into extracellular
matrix, and the mutation resulted in dramatic alterations in collagen fibril structure. The two-exon skip occurred
in transcripts in which intron 5 was removed rapidly relative to introns 4 and 6, leaving a large (270 nt) composite
exon that can be skipped in its entirety. The transcripts in which only exon 5 was skipped were derived from those
in which intron 6 was removed prior to intron 5. The use of cryptic acceptor sites in exon 5 occurred in transcripts
in which intron 4 was removed subsequent to introns 5 and 6. These findings suggest that the order of intron
removal plays an important role in the outcome of splice-site mutations and provide a model that explains why
multiple products derive from a mutation at a single splice site.
Introduction
Type V collagen, a minor component of many connective
tissues, plays a role in the regulation of the size and con-
figuration of fibrils of the much more abundant com-
ponent type I collagen (van der Rest and Garrone 1991).
The major variant of type V collagen in most tissues is a
heterotrimer that is composed of two pro-a1(V) chains
and a single pro-a2(V) chain, encoded by the COL5A1
and COL5A2 genes, respectively. The two genes are part
of the fibrillar-collagen gene family and encode chains
with uninterrupted triple helices. COL5A1 differs some-
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what from the major fibrillar-collagen genes in intron-
exon structure and encodes a very large amino-terminal
(N-)propeptide (Greenspan et al. 1991a; Takahara et al.
1991, 1995) that is similar to those encoded by the
COL11A1 and COL11A2 genes (Zhidkova et al. 1993;
Tsumaki and Kimura 1995). This propeptide (extending
from the signal-peptide cleavage site to the beginning of
the major triple helix), which consists of 522 amino
acids, is composed of an amino-terminal PARP (proline-
arginine–rich protein) globular subdomain, which bears
some homology to similar domains in thrombospondin
and von Willebrand factor (Bork 1992); a globular sub-
domain, known as the “variable region”; and a small
collagenous subdomain. A site for proteolytic maturation
is encoded in exon 5, and cleavage at this site removes
the PARP subdomain (Imamura et al. 1998; Unso¨ld et al.
2002). The retained variable region projects beyond the
surface of large heterotypic fibrils composed of both type
I and type V collagen and has been suggested to regulate
fibril structure (Linsenmayer et al. 1993). These hetero-
typic fibrils are found in skin and other tissues.
Fibril architecture is altered in skin and other tissues,
in individuals with Ehlers-Danlos syndrome (EDS) types
I (MIM130000) and II (MIM130010) (the classical form
of the disorder), which are clinically characterized by very
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soft hyperextensible skin, large- and small-joint hyper-
mobility, abnormal scar formation, and easy bruising
(Beighton 1993; Steinmann et al. 1993). There is increas-
ing evidence that mutations in either of the two type V
collagen genes are the usual causes of the phenotypes of
EDS types I and II, but mutations have also been iden-
tified, in a small number of individuals, in the COL1A1
(Nuytinck et al. 2000), COL1A2 (Sasaki et al. 1987;
Hata et al. 1988; Nicholls et al. 2001), and tenascin X
(TNX) (Burch et al. 1997; Schalkwijk et al. 2001) genes.
Exon-skipping mutations in the triple-helix–encoding re-
gion of COL5A1 (Nicholls et al. 1996); alterations, in
the C-propeptide of pro-a1(V), that interfere with chain
assembly (Wenstrup et al. 1996; De Paepe et al. 1997);
a translocation that deletes the entire carboxyl-terminal
half of the coding sequence (Toriello et al. 1996); and
mutations that alter the triple helix of pro-a2(V) (Mich-
alickova et al. 1998) have all been found. Collectively,
these seem to account for less than one-fourth of all mu-
tations. Recently, it has become clear that COL5A1mu-
tations that result in the lack, usually as a result of very
unstable mRNA, of protein synthesized from one null
allele account for a significant proportion of the remain-
der (Schwarze et al. 2000; Wenstrup et al. 2000).
Here we characterize (1) the first mutation reported to
alter the N-propeptide of the pro-a1(V) chain and (2) a
novel response to an acceptor-site mutation. Such N-
propeptide mutations are unknown in the other fibrillar-
collagen genes. The patient whom we studied has an ac-
ceptor-site mutation (IVS4-2ArG), in COL5A1 intron 4,
that leads tomultiplemRNAproducts: themajor product
lacks the sequences of exons 5 and 6, another product
lacks the sequence of exon 5 alone, and two additional
products are missing 12 or 15 nt at the 5′ end of exon
5. All mRNA products are in frame and should produce
protein products. The two products missing the sequence
of exon 5 lack the PARP-domain cleavage site and also
lack two of the four cysteines that are normally found
in the N-propeptide. The patient’s cells incorporate mu-
tant pro-a1(V)–derived chains, with abnormal-sized N-
propeptides, into extracellular matrix in culture and
synthesize collagen fibrils with a bizarre architecture,
providing evidence that pro-a1(V) N-propeptide se-
quences play an important role in fibrillogenesis. The
unusual occurrence of a two-exon skip is best explained
by the order of intron removal in this region such that
intron 5 is removed rapidly, in most transcripts, with
respect to introns 4 and 6, so that a large exon (resulting
from the fusion of exons 5 and 6) can then be skipped.
This novel mechanism suggests that intron splice order
may be an important factor in the understanding of some
outcomes of splice-site mutations and that multiple prod-
ucts are derived from different splicing pathways.
Patient, Material, and Methods
Case Report
When seen in 1995, the patient was a 5-year-old boy.
He was adopted, and no information was available
about his biological parents. He was 37 inches tall (!5th
percentile) and weighed 32 pounds (5th percentile). He
had very soft, hyperextensible skin and had scars, from
previous injuries, on his forehead, as well as scars and
hyperpigmentation on his shins. He could touch his fin-
gers to the dorsum of each arm, with passive flexion.
His large joints had mild hypermobility, and all small
joints appeared to be hypermobile. The physical findings
for the patient were compatible with the diagnosis of
Ehlers-Danlos syndrome type I (Beighton et al. 1998).
A dermal-punch-biopsy sample was taken after assent
from the patient and consent from the parents were ob-
tained. Cells were grown from the biopsy sample and
were then maintained in culture as described elsewhere
(Bonadio et al. 1985).
Preparation of cDNA and Genomic DNA
Total cellular RNA and genomic DNA were extracted
from cultured dermal fibroblasts from the patient and
from a control individual, by use of the RNeasy Mini Kit
(Qiagen) and QIAamp DNA Mini Kit (Qiagen), respec-
tively. In addition, nuclear and cytoplasmic RNA were
prepared from cultured fibroblasts from the patient and
a control cell strain, as described elsewhere (Schwarze et
al. 1999). cDNA was synthesized by the priming of total
RNA, with random hexamers, in the presence of Super-
script II reverse transcriptase (Gibco BRL) or the priming
of nuclear and cytoplasmic RNA separately after treat-
ment with DNase I (Boehringer Mannheim) for 20 min
at 37C, with the incubation buffer recommended by the
manufacturer. To check for residual genomic DNA in the
RNA preparation, we performed a control PCR without
prior reverse transcription.
Amplification of the COL5A1 Coding Sequence
and Sequence Determination of Aberrant Products
COL5A1 coding sequences were amplified in six over-
lapping fragments, with primer sets that have been pub-
lished elsewhere (Schwarze et al. 2000), and the frag-
ments were separated on 6% polyacrylamide gels. Extra
PCR bands that were derived from the patient’s cDNA
were excised from the gel and reamplified. Sequences of
the reamplification products were determined, by the
dideoxy-chain–termination method, either directly or
after cloning into the PCR II vector, according to in-
structions provided in the TA cloning kit (Invitrogen).
An additional PCR that amplified the products from
the abnormal and normal COL5A1 alleles in the region








P3 GTCCAGCCTCAGAGCCATTGTCAG 3, 4
P4 ACTCCAGGCTCTCAGAGCAATGTG 3, 4
IN 4S TTCAAGGCATGGGGCTGTGTCT 5
IN 4S mod TCTGGACTTTCCCCTGCTTCAAGGC 5
E 6A GGGTCTTCGTAGTAGGGGTATTCGTAGT 5
IN 6A GCCCAGCCCAACCCAGTCC 5
NOTE.—“IN” denotes intron-derived oligonucleotides; “E” denotes exon-derived oligonucleotides.
affected by the mutation was performed. This reaction
used a sense primer, in exon 4 (5′-GATCGACATCAATG-
GCATCATCG-3′), that was end-labeled with g[32P]-ATP
(3,000 Ci/mmol; Amersham) by T4 polynucleotide kinase
(New England BioLabs) and an antisense primer, in exon
7 (Schwarze et al. 2000) (1 min each at 94.5C, 58C,
and 72C, for 30 cycles). The products were separated on
a 7% polyacrylamide gel, which was dried, and the ra-
dioactive bands were visualized by autoradiography.
Southern Blots
Genomic DNA was extracted from cultured der-
mal fibroblasts by use of standard phenol/chloroform
methods (Ausubel et al. 1987). DNA samples were
transferred from 0.8% agarose gels to Hybond-N
membranes (Amersham), which were hybridized and
washed as described elsewhere (Takahara et al. 1994).
The hybridized probe was a 255-nt PCR product that
was amplified, with primers 5′-ATCCAGCAGCTGCT-
CTTTGTCTCG-3′ and 5′-CTCTGTGGTTTCTTTGG-
CAGCTTCCAC-3′, from human placenta cDNA tem-
plate (Clontech) and that corresponded to sequences
contained in COL5A1 exons 5 and 6, comprising nu-
cleotides 890–1144 of the published pro-a1(V) cDNA
sequence (Greenspan et al. 1991a).
Synthesis of Riboprobe for RNA Protection
Total RNA was extracted from dermal fibroblasts by
use of TRIzol reagent (Gibco BRL), according to theman-
ufacturer’s protocol. A 675-bp BamHI-NaeI restriction
fragment, comprising nucleotides 856–1530 of the pub-
lished human pro-a1(V) cDNA sequence (Greenspan et
al. 1991a), was cloned between the BamHI and EcoRV
sites of the vector pBluescript II KS (Stratagene); the
resultant plasmid was linearized at the BamHI site; and
a [32P]-labeled 734-base riboprobe was generated using
RNA polymerase T3 in the presence of g[32P]GTP.
Conditions for the annealing of the antisense probe to
20 mg fibroblast RNA or yeast tRNA and for the incu-
bation with RNases A and T1 were as described else-
where (Greenspan et al. 1991b).
PCR Amplification
The following amplifications employed high-fidelity/
long-distance PCR conditions (Barnes 1994; Cheng et
al. 1994) and used Taq Extender PCR additive (Stra-
tagene), according to the manufacturer’s protocols. Am-
plifications to obtain the probe for the Southern blot
(shown in fig. 2A) and the genomic region between prim-
ers P1 and P2 (in fig. 2B) were performed with dena-
turation at 94C for 3 min, followed by 32 cycles of
98C for 10 s with annealing and extension at 68C.
This two-step profile was begun at 68C for 5 min, with
autoextension adding 15 s per cycle thereafter. Final in-
cubation was at 70C for 8 min. Conditions for ampli-
fication, with primers P3 and P4, of the polymorphic-
length repeat sequence in intron 6 were the same as
above except that annealing and extension were begun
at 68C for 1.5 min, with autoextension adding 2 s per
cycle. Primers P1–P4 are listed in table 1.
Exon Trapping
Allele A or allele B genomic sequences extending, in
intron 4, from an EcoRI site 103 bp upstream from exon
5, to a BamHI site in intron 7, 395 bp downstream from
exon 7, were separately inserted between the EcoRI and
BamHI sites of pBluescript II KS and were then excised
with EcoRI andXbaI. The latter sequence cut at theXbaI
site within the pBluescript polylinker, 7 bp beyond the
BamHI site, giving the inserts ends that were compatible
for cloning between the EcoRI and NheI sites of the
exon-trapping vector pSPL3 (Gibco BRL). Constructs
were then transfected into COS-7 cells (American Type
Culture Collection number CRL-1651), and total RNA
was isolated and was reverse transcribed into first-strand
cDNA, which was then amplified, according to the man-
ufacturer’s instructions, with vector-specific primers. Am-
plification products were sequenced after their subcloning
into the pGEM-5Zf() vector (Promega) and after use of
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the Sequenase II kit (USB), as described elsewhere (Taka-
hara et al. 1994).
Determination of Order of Intron Removal
in the COL5A1 Gene
To determine the order of intron removal between
exons 4 and 7 of COL5A1 pre-mRNA, we analyzed the
splicing intermediates by a PCR strategy described else-
where (Kessler et al. 1993; Schwarze et al. 1999). Nu-
cleotide sequences of the primers described in the legend
to figure 5 are listed in table 1. PCR was performed in
a 50-ml volume that contained 1 ml cDNA derived from
nuclear RNA after incubation of cultured control and
patient fibroblasts with actinomycin D for 0, 5, 10, 20,
40, and 60 min; 5 ml 10 # PCR buffer with 20 mM
MgCl2, 0.2 mM dNTPs, 1 U of Taq polymerase (Boeh-
ringer Mannheim); and 10 pmol of each primer. Am-
plifications were done through 30 cycles of denaturation
at 94.5C for 1 min, primer annealing at 60C for 45 s,
and primer extension at 72C for 1 min 45 s. All PCR
products (10-ml aliquots) were separated on 7% poly-
acrylamide gels, and the bands were visualized by eth-
idium bromide staining. For the estimation of the con-
tribution of alleles A and B to splice intermediates, bands
of interest were excised from gels, the DNA fragments
were reamplified with the original primer sets, the ream-
plification products were cut with PstI (New England
BioLabs), and the products were analyzed by PAGE.
Protein Analysis
Fibroblasts were cultured for 1 wk in the presence of
200 mM ascorbate-2-phosphate, as described elsewhere
(Hazeki et al. 1998). After being washed with PBS, cell
layers were scraped into extraction buffer (PBS containing
1 M NaCl, 0.5% NP-40, 5 mM EDTA, 1 mM N-ethyl-
maleimide, 1 mM p-aminobenzoic acid, and 0.1 mM
phenylmethylsulfonyl fluoride), were freeze thawed once,
and were then stirred overnight at 4C. Insoluble material
that contained matrix was collected, in this and subse-
quent steps, by centrifugation at 15,000 rpm at 4C for
10 min in an Eppendorf centrifuge; was rinsed twice with
extraction buffer; and either was solubilized in 2% SDS-
gel sample buffer prior to electrophoresis orwas subjected
to bacterial collagenase treatment (as described by Ima-
mura et al. [1998]), which degrades themajor collagenous
domains of collagen molecules, thus liberating noncol-
lagenous domains from the insoluble matrix. Material
liberated from matrix samples by collagenase was mixed
with 4 # SDS-gel sample buffer. Samples were analyzed
by SDS-PAGE with either a 5% running gel and a 4%
stacking gel or a 4%–15% gradient gel and were detected
by immunoblotting, with a polyclonal antibody described
elsewhere (Unso¨ld et al. 2002), directed against sequences
in the variable subdomain of the N-terminal globular por-
tion of the human pro-a1(V) chain.
To compare efficiencies of secretion of type V pro-
collagen, we compared the ratio of type V:type I col-
lagen in the matrix of patient and control fibroblasts.
Cells cultured for 3 wk in the presence of 200 mM as-
corbate-2-phosphate were washed twice with PBS; were
scraped into 200 mM sodium phosphate buffer (pH 7.2)
that contained 5 mM EDTA, 1 mM N-ethylmaleimide,
0.1 mM phenylmethylsulfonyl fluoride, and 1 mM p-
aminobenzoic acid; and were suspended overnight at
4C. Insoluble material was washed twice in double-
distilled water containing the same inhibitors and was
then treated with pepsin (0.1 mg/ml in 0.5M acetic acid)
overnight at 4C. Insoluble material was collected and
treated with pepsin (0.1 mg/ml in 0.5 M acetic acid)
overnight at room temperature. Solubilized supernatants
from the two pepsin extractions were pooled, and the
collagenous proteins were concentrated by precipitation
with 20% NaCl. Insoluble residue that remained after
the two pepsin treatments was suspended in SDS-gel
sample buffer with 5% 2-mercaptoethanol, by boiling
for 5 min. Proteins in both pepsin-soluble and -insoluble
material were separated by SDS-PAGE and were stained
with Coomassie Blue, and bands were scanned and
quantified using Image software (National Institutes of
Health). The ratios of type V:type I collagen were es-
timated by obtainment of the ratios of a1(V):a2(I)
chains, which were 0.56 for the patient and 0.54 for the
control individual, when values for pepsin-soluble and
-insoluble materials were combined.
Electron-Microscopic Examination of Collagen Fibrils
Synthesized by Cultured Cells
Dermal fibroblasts from the patient and from a con-
trol individual were grown in culture for 3 wk, with
daily addition of new medium that contained ascorbic
acid (50 mg/ml). Cells and matrix were fixed in culture
dishes, were embedded in Epon, and were thin-sec-
tioned, stained, and examined by transmission electron
microscopy, as described elsewhere (Smith et al. 1992).
Results
Multiple Splice Products from a COL5A1 Allele
RT-PCR was performed on total RNA from the pa-
tient’s dermal fibroblasts, with primers that amplified
COL5A1 and COL5A2 mRNA sequences in six and
five overlapping fragments, respectively. Only the frag-
ment of COL5A1 mRNA that included the region be-
tween exons 1 and 7 was abnormal when products were
analyzed on polyacrylamide gels. When the region be-
tween exons 4 and 7 was amplified, to narrow the ab-
normal domain, three smaller-than-expected fragments
were apparent (fig. 1A). Sequence determination of the
two smallest products showed that one was missing the
132 nt of exon 5 and that the other was missing both
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Figure 1 Detection of abnormalities between exons 4 and 7 se-
quences in RNA from one of the patient’s COL5A1 alleles. A, Ampli-
fication ofCOL5A1 cDNA from a control individual (C) and the patient
(P) with a sense primer, end-labeled with g[32P]-ATP (see the “Patient,
Material, andMethods” section), in exon 4 andwith an antisense primer
in exon 7. A single major band is apparent in the sample from the control
individual; the sample from the patient has the normal-sizedbandderived
from the normal COL5A1 allele, one band just below that representing
fragments produced by use of two separate cryptic acceptor sites in exon
5 (removing 12 or 15 nt from exon 5), and two lower bands that result
from skipping of either exon 5 or both exons 5 and 6. B, Quantitative
RNase-protection analysis. Conditions for labeling and annealing of the
antisense probe to yeast (Y), control (C), and patient (P) RNA are de-
scribed in the “Patient, Material, and Methods” section. Nuclease-pro-
tected fragments were separated on a denaturing 6% polyacrylamide
gel. Sizes (in nt) of protected fragments are given.C, Schematic depicting
the relationship of the riboprobe and protected fragments to COL5A1
exon sequences. BamHI and NaeI sites used in the making of the
probe—as well as a cryptic splice site used in allele B, an AT-rich region
that may result in partial cleavage by RNase due to “breathing” of the
RNA duplex, and an SNP at nucleotide 1318 (T/C)—are shown. Awavy
line represents non-COL5A1 vector sequences on the riboprobe.
the 132 nt of exon 5 and the 138 nt of exon 6. When
fragments cloned from the gel region that contained the
band slightly smaller than the normal-sized band were
analyzed, two additional shorter fragments were iden-
tified. In one, the first 12 nt from the 5′ end of exon 5
were deleted, and, in the other, the first 15 nt from the
same exon were deleted. All four products retained the
normal reading frame, and all were found in the cyto-
plasm (not shown).
A quantitative RNase-protection assay was performed,
to measure relative amounts of the various spliced RNA
forms produced by the patient’s COL5A1 alleles and to
ascertain whether, as appeared to be the case on the basis
of the RT-PCR results (above), the product of the two-
exon skip was the major species derived from the mu-
tant allele. The patient’s RNA was found to protect ap-
proximately one-half the amount, as did control RNA,
of a 675-nt fragment corresponding to correctly spliced
mRNA (fig. 1B)—consistent with the interpretation that
only one of the patient’s COL5A1 alleles produces cor-
rectly spliced mRNA. The patient’s RNA also protected
an ∼638-nt fragment, not protected by control RNA,
that corresponded to mRNA derived by use of the exon
5 cryptic splice sites. However, an even greater amount
of a 380-nt fragment, corresponding to RNA from
which both exons 5 and 6 were spliced out, was pro-
tected by the patient’s RNA, demonstrating that the pa-
tient’s fibroblasts produce more of this form of RNA
than of RNA that has used exon 5 cryptic splice sites.
In fact, since the riboprobe was uniformly labeled along
its length, the RNase-protection autoradiogram under-
represents the abundance of the mRNA that corresponds
to the relatively small 380-nt fragment. A 518-nt frag-
ment, corresponding in size to RNA from which exon
5 but not exon 6 was spliced out (figs. 1B and 1C), was
protected by the patient’s RNA, with lesser amounts
protected by control RNA. The lesser amounts protected
by control RNA may correspond to partially processed
nuclear RNA, since total RNA was used. However, this
fragment was not seen after amplification of the cDNA
(fig. 1A), suggesting that it is an artifact of the RNase-
protection assay, perhaps resulting from the AU-rich
nature of sequences at the juncture of exons 5 and 6
(AAUAUUA [nucleotides 1011–1017]), which may re-
sult in limited cleavage by RNase at this site because of
“breathing” of the RNA duplex (Ausubel et al. 1987).
A 462-nt fragment protected by both patient and control
RNA (figs. 1B and 1C) probably resulted from limited
cleavage at an SNP at nucleotide 1321 (in exon 7; see
fig. 1B), which is T both in the published sequence
(Greenspan et al. 1991a) and in the cDNA used to pre-
pare the riboprobe but which is C in both COL5A1
alleles of both the patient and the control individual.
Identification of a Mutation (IVS4-2ArG)
in the Splice-Acceptor Site of Intron 4
To identify the genomic defect(s) leading to the aberrant
forms of COL5A1 mRNAs described above (see the
“Multiple Splice Products from a COL5A1 Allele” sub-
section), we performed Southern blot analysis of the pa-
tient’s genomic DNA, with a cDNA probe that contained
the sequences of exons 5 and 6. As can be seen, the blot
detected restriction fragments that correspond in size to
those of the control individual, aswell as a larger fragment
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Figure 2 Analysis of patient’s genomic DNA. A, Southern blot analysis, with a probe for COL5A1 exons 5 and 6. Genomic DNA samples
from the patient (P) and from the control individual (C) were cleaved with BamHI (B) or Pst I (P) and were probed for exon 5 and 6 sequences.
B, Summary of features in the COL5A1 region affected in the patient. Exons are denoted by vertical bars or unblackened boxes. The exons are
connected by horizontal lines that depict introns drawn approximately to scale. Arrowheads denote the positions of PCR primers. A circled P marks
the site of a polymorphic PstI site in exon 5 of the patient’s allele A. This polymorphic site contributes to the size differences between the patient’s
allele A and allele B fragments and is also used as a marker in figure 5. Here and in figure 5, the control individual is also seen to be heterozygous
for the PstI site. The obligatory ag dinucleotide of the intron 4 splice-acceptor site is shown for allele A. In allele B, an ArG transition (marked
with an asterisk [*]) converts this dinucleotide ag to gg (IVS4-2ArG). Two cryptic splice-acceptor sites used by some allele B RNA transcripts are
boxed within a 17-nt sequence shown for the allele B intron 4/exon 5 junction; intron sequences are denoted by lowercase letters, and exon sequences
are denoted by uppercase letters. Restriction sites in the upper section of the panel were derived elsewhere (Takahara et al. 1995). Underlined
restriction sites in the middle section of the panel were inferred from the Southern blot shown here and from another Southern blot not shown; all
other restriction sites in the middle section of the panel were derived from complete sequencing of amplification products generated using primers
P1 and P2. A schematic in the bottom section of the panel illustrates relationships between the restriction fragments seen in panel A and various
features of the region of COL5A1 affected in the patient. B p BamHI; E p EcoRI; P p PstI; S p SacI; X p XhoI.
not seen in the control individual, after digestion of DNA
with BamHI or PstI (fig. 2A). PCR amplification of the
patient’s genomic DNA, with primers located just up-
stream from exon 5 (P1) and within exon 7 (P2) (see fig.
2B), yielded two different-sized products of∼3.5 and∼3.8
kb (not shown), which were designated alleles “A” and
“B,” respectively. The ∼300-bp size difference reflected
different numbers of a 56-bp repeat sequence in intron
6. This genomic segment, with nine different alleles de-
tected, is highly polymorphic in the general population
(table 2). Alleles 1 and 2, the two smallest alleles, contain
five and six of the 56-bp repeats, respectively. The pa-
tient’s alleles A and B, respectively, corresponded in size
with alleles 4 and 6 in the general population. Since the
∼300-bp size difference between these two normally oc-
curring repeat-sequence alleles is sufficient to account for
the size differences between the normal- and abnormal-
sized restriction fragments in the genomic Southern blot
(fig. 2A), it is unlikely that these size differences are related
to the patient’s EDS phenotype.
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Table 2














NOTE.—The patient had alleles 4 (normal) and 6 (mutant). The
repeat sequence is AGCG(TG)3CATGCGGGCACGGG(TG)2CATGA-
GCC(TG)5AGCG(TG)3. (An SphI site that was present in some repeats,
but absent in others, is underlined.)
a Frequencies were estimated on the basis of 96 chromosomes from
unrelated individuals. Observed heterozygosity was 0.73. The poly-
morphism-information-content value was 0.69.
Figure 3 DNA sequence through the acceptor splice junction of
intron 4 in the two alleles (A and B) from the patient. In the normal
allele, the intron ends with CAG, whereas, in the mutant allele, there
is a substitution of G for the A so that the intron ends with CGG.
Intron sequences are denoted by lowercase letters, and exon sequences
are denoted by uppercase letters.
In addition to the difference in the length of the poly-
morphic repeat sequence in intron 6, two additional
DNA sequence differences were observed between alleles
A and B: (1) an ArG transition at the 2 position of
the obligatory AG dinucleotide of the intron 4 splice-
acceptor site (i.e., IVS4-2ArG) in allele B (figs. 2B and
3); and (2) substitution of a T for the C at nucleotide
738 (i.e., 738CrT, with the A of the initiator methionine
being reference position 1 in cDNA) in allele A, in the
coding region of exon 5 (fig. 2B). The latter substitution
introduced a PstI site into exon 5 of allele A (fig. 2B)
that did not affect the codon. In fact, the control indi-
vidual was also found to be heterozygous for this PstI
site. PstI restriction and direct sequencing of RT-PCR
products that correspond to this region showed that, as
expected on the basis of the splice-site mutation in allele
B, the majority of expressed sequences that contained
exon 5 were derived from allele A.
Splice-Junction Sequences That Flank the Two Spliced
Exons 5 and 6 in the Patient’s Mutant Allele Are Not
Sufficient to Produce the Two-Exon Skip
The skipping of two exons as a consequence of a single
splice-acceptor mutation is unexpected. One factor that
could contribute to the skipping of both exons 5 and 6
is the poor fit of the intron 6 splice-donor site—which
contains pyrimidines, rather than purines, at positions 3
and 4 (i.e., AGgtctgg, instead of AGgtaagt) (Takahara et
al. 1995) and the donor-site consensus sequence (Shapiro
and Senapathy 1987). To determine whether the splice-
junction sequences that flank exons 5 and 6 in the pa-
tient’s mutant allele were sufficient to produce the skip-
ping of the two exons, the portions of alleles A and B
comprising 103 bp of intron 4, all of exons 5–7, all of
introns 5 and 6, and 395 bp of intron 7 were separately
placed in an exon-trapping vector and transfected into
COS-7 cells. Genomic sequences that included exon 4 and
the remainder of intron 4 were not included in these con-
structs because of the large size (∼26 kb) of intron 4
(Takahara et al. 1995). As expected, the construct that
contained sequences from normal allele A produced only
correctly spliced mRNA that contained exons 5–7 (fig.
4). Surprisingly, the construct that contained the mutant
allele B sequence gave rise to only one major mRNA
species, somewhat smaller than that produced by the nor-
mal allele (fig. 4). This product, identical to one of the
low-abundance splice products identified in the patient’s
fibroblast mRNA, resulted from use of the cryptic splice
site, within exon 5, constituted by an AG dinucleotide
pair 11 and 12 nt from the normal intron 4/exon 5 junc-
tion (see fig. 2B). The absence of additional splice prod-
ucts in this system demonstrated that exons 5 and 6 (and
7) splice-junction sequences and other sequences con-
tained within the exon-trapping vector were insufficient
for the replication, in the patient’s allele, of the effects of
the mutation, suggesting that additional COL5A1 se-
quences were involved in the production of the full range
of splice products found in the patient’s fibroblastmRNA.
Order of Intron Removal in COL5A1 Precursor mRNA
Indicates That Rapid Removal of Intron 5 Could
Account for the Two-Exon Skip
Cells from the patient and from a control individual
were incubated with actinomycin D, to stop transcrip-
tion, and nuclear RNA was harvested after 0, 5, 10, 20,
40, and 60 min and was reverse transcribed to cDNA.
Paired intron/exon or intron/intron primers were used
to amplify different regions between intron 4 and exon
7 in the unspliced or partially spliced precursor mRNA,
and the products were separated by PAGE. When an
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Figure 4 Spliced products after transfection of COS-7 cells with
constructs that contain the normal andmutant sequences. Transfection
with a construct containing wild-type normal (N) sequences produces
a single band that corresponds to correctly spliced mRNA containing
exons 5–7, whereas transfection with a construct containing the pa-
tient’s mutation (P) produces a single major band that corresponds to
mRNA resulting from use of a cryptic splice site constituted by an AG
dinucleotide pair 11 and 12 nt from the normal intron 4/exon 5 junc-
tion. M p size markers.
intron 4/exon 6 primer pair was used to determine the
relative order of intron 4 and intron 5 removal, the full-
length product was quickly lost in the control cells but
remained present for 60 min in the patient cells (fig. 5A).
This is consistent with a pathway in which intron 4 can
be removed prior to removal of intron 5 in control cells.
In the patient cells, this product contained only mRNA
derived from the mutant allele (fig. 5B), consistent with
the delayed removal of intron 4, presumably as a con-
sequence of the acceptor-site mutation. A shorter prod-
uct, from which intron 5 had been removed, persisted
in both cell strains, although, in the patient cells, this
product was derived largely from the mutant allele (fig.
5C). In both cell strains, this indicates that there is a
separate pathway in which intron 5 is removed prior to
excision of intron 4.
When the intron 4/intron 6 primer pair was used to
determine whether there was a pathway in which intron
5 was removed prior to the two flanking introns, the
amount of full-length product rapidly declined in the
control cells but remained abundant in the patient cells
(fig. 5D). A partially spliced product, from which intron
5 was removed but still containing introns 4 and 6, re-
mained apparent in both cells. In the patient cells, this
product was derived from the mutant and normal alleles
in an approximately equal ratio, indicating that, in these
cells, the pathway in which intron 5 was removed prior
to the flanking introns was equally active in both alleles
(fig. 5E). In additional studies, with primers in intron 5
and exon 7, very little of the full-length product was
apparent, but the product that contained intron 5 but
lacked intron 6 was present, consistent with a pathway
in which intron 6 was removed prior to intron 5 in both
patient and control cells (data not shown).
These data are consistent with a model in which there
are multiple pathways of ordered intron removal in the
region between exons 4 and 7 (fig. 6). In the control
cells, there are pathways in which intron 4 is removed
prior to intron 5, in which intron 5 is removed prior to
intron 4, in which intron 5 is removed prior to intron
6, and in which intron 6 is removed prior to intron 5.
In the cells from the patient, the removal of intron 4
appears to be delayed as a consequence of the acceptor-
site mutation, but the removal of neither intron 5 nor
intron 6 is appreciably altered. As a result, in most in-
stances, intron 5 is spliced first (fig. 6) in the mutant
allele. For the mutant allele, the next step in this splicing
pathway can be either the skipping of the fused “5-6”
exon or the removal of intron 6. The latter product,
which contains fused exons 5–7 sequences, is then a
substrate for use of the cryptic exon 5 acceptor sites.
The product of the single exon 5 skip is generated from
the pathway in which intron 6 is removed prior to intron
5 (fig. 6).
Cultured Fibroblasts Incorporate Abnormal Pro-a1(V )
Chains into Extracellular Matrix and Assemble Collagen
Fibrils with Very Abnormal Structures
To determine the effects of the patient’s mutation at
the protein level, we examined dermal fibroblasts cultured
from the patient and from a control individual for pro-
a1(V)–derived chains that were incorporated into the ex-
tracellular matrix associated with cell layers. The patient’s
mutation did not appear to result in a secretion defect for
type V procollagen, as ratios of type V:type I collagen
were essentially the same in patient and control matrices
(see the “Patient, Material, and Methods” section). Pa-
tient and control fibroblast matrix each contained mul-
timeric forms of pro-a1(V)–derived chains (fig. 7A), prob-
ably from intact type V collagen molecules covalently
cross-linked to each other and to chains of type I collagen,
as occurs in heterotypic fibrils (Niyibizi and Eyre 1994).
In addition, the matrix from each contained monomeric
pro-a1(V)–derived forms that corresponded in size to
pNa1(V) (fromwhich the C-propeptidewas removed, but
in which the full-length N-propeptide was intact) andma-
ture a1(V) chains (from which the C-propeptide and the
PARP subdomain of the N-propeptide were removed, but
which retained the N-propeptide variable region subdo-
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Figure 5 Amplification of regions between introns 4 and 6 in unspliced or partially spliced COL5A1 precursor mRNA (cDNA) isolated from
cultured fibroblasts after incubation with actinomycin D (Act.D) for 0, 5, 10, 20, 40, and 60 min. A, Amplification with an intron 4 (IN 4S) and
exon 6 (E 6A) primer pair. The full-length product was quickly lost in the control cells but remained present for 60 min in the patient cells. In both
cell strains, the shorter product, from which intron 5 had been removed, persisted. B and C, PstI restriction fragments of excised and reamplified
full-length (intron 4–exon 5–intron 5–exon 6) and partially spliced (intron 4–exon 5–exon 6) products, respectively, derived from the PstI/ control
individual (C) and the PstI/ patient (P). In the patient cells, the full-length product (B) contained mRNA derived only from the mutant (PstI)
allele, and the product from which intron 5 had been removed (C) was derived largely from the mutant allele. D, With an intron 4 (IN 4S mod)
and intron 6 (IN 6A) primer pair, the amount of full-length product rapidly declined in the control cells but remained abundant in the patient cells.
The partially spliced product, which removed intron 5 but contained introns 4 and 6, remained. E, PstI restriction fragments of excised and
reamplified partially spliced (intron 4–exon 5–exon 6–intron 6) product derived from the PstI/ control individual (C) and patient (P). In the patient
cells, this product was derived from the mutant and normal alleles in approximately equal amounts. Molecular weight marker is l-DNA cut with
PstI. gen p genomic DNA control individual; NC p PCR-reagent control individual; /, /, and / p PstI-restricted cDNAs reverse
transcribed from control RNA samples from individuals who were homozygous positive, heterozygous, and homozygous negative, respectively, for
a polymorphic PstI site in COL5A1 exon 5.
main) (see figs. 7A, 7B, and 7D). Molecules that retained
C-propeptides were not observed in either sample, con-
sistent with the probability that retained C-propeptides
prevent the incorporation of type V procollagen–derived
forms into matrix (Fessler and Fessler 1987). Notably,
matrix made by the patient’s cells contained two novel
pro-a1(V)–derived chains not seen in controlmatrix,with
mobilities intermediate between those of pNa1(V) and
a1(V) forms (figs. 7A and 7B). The mobility differences
between the novel chains and the normal a1(V) and
pNa1(V) forms appear to reflect the different molecular
weights of the chains translated from the different ab-
normal mRNA species. This conclusion is supported by
analysis of matrix samples treated with bacterial collag-
enase. Such treatment of control matrix liberated frag-
ments of 85 and 50 kD (fig. 7C) that corresponded, re-
spectively, to the full-length N-propeptide and to that
portion of the N-propeptide that remained in mature
a1(V) chains subsequent to excision of the PARP sub-
domain by bone morphogenetic protein–1 (BMP-1) (fig.
7D). In contrast, similar treatment ofmatrix samples from
the patient’s cells produced, in addition to the 85-kD
form, two novel bands of 76 and 63 kD, which probably
represent mutant N-propeptides missing sequences en-
coded by exon 5 (76 kD) and by both exons 5 and 6 (63
kD) (figs. 7C and 7D). The very small amount of the 50-
kD band in the patient sample reflects the relatively small
amount of total protein produced by the patient’s cells
plus the decreased access that collagenase appears to have
to mature a1(V) chains, compared to pNa1(V) forms,
in matrix samples—for example, compare the ratio of
pNa1(V):a1(V) chains to that of 85 kD:50 kD forms
in the control lanes in figs. 7A and 7C, respectively.
When dermal fibroblasts from the patient and from a
control individual were grown in culture for 3 wk, the
fibrils formed by the control cells were small and com-
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Figure 6 Predicted pathways of intron removal in the mutant COL5A1 allele (the asterisk [*] indicates IVS4-2ArG), in which either
intron 5 or intron 6 is removed first. If intron 5 is removed first, then the next step in this pathway can be either skipping of both exons 5 and
6 or removal of intron 6. The latter product is then a substrate for use in the cryptic exon 5 acceptor sites. The other pathway in which intron
6 is removed prior to intron 5 leads to the product of a single exon 5 skip.
pact with normal periodic staining. The fibrils from the
patient cells had a complex architecture with a longi-
tudinal twist (fig. 8), reminiscent of fibrils seen in skin
from individuals with EDS type I (Vogel et al. 1979;
Schwarze et al. 2000).
Discussion
We think that the findings in this study are important
for two reasons: First, they show that the complex out-
come of splice-site mutations can be explained by anal-
ysis of the order of intron removal. Second, they dem-
onstrate that the amino-terminal end of the pro-a1(V)
chain plays a significant role in fibril formation in the
extracellular matrix.
In most previous reports of mutations at single splice
junctions that result in the skipping of two or more
exons (Schneider et al. 1993; Hayashida et al. 1994;
Haire et al. 1997; Minami et al. 1999; Fang et al. 2001),
the product of the multiexon skip is a low-abundance
species. Usually, these are seen in the context of an al-
ternatively spliced adjacent exon (Schneider et al. 1993;
Hayashida et al. 1994; Minami et al. 1999), so that the
effects of the mutations add to and are obscured by the
unusual splicing features of the domain. An exception is
a splice-donor mutation (IVS12a1GrA), in the NF1
gene, in which exons 11 and 12a are skipped (Fang et
al. 2001). In that instance, Fang et al. (2001) propose
that there is excision, by use of the intron 10c donor site
and intron 12a acceptor site, of the entire region. How-
ever, no demonstration of this pathway is provided, and
the in vitro and transfection studies that were done use
truncated intron extensions, which, as we found, may
distort the outcome. In contrast to previous reports, the
mutation that we describe is not in the context of an
alternatively spliced region, and the two-exon skip is the
major outcome.
The mechanisms whereby mutations at a single splice
junction result in the skipping of multiple exons are not
apparent from current exon- and intron-definition mod-
els of splicing (Berget 1995). We think that, by adding a
mechanistic structure to the usual exon- and intron-def-
inition models, analysis of the order of intron removal
provides a way to explain the two-exon skip. The cells
from the patient whom we studied derive multiple in-
frame products from the mutant allele, which harbors
the IVS4-2ArG sequence alteration. These products in-
clude one in which both exons 5 and 6 are skipped (the
major product), one in which only exon 5 is skipped,
and two other minor products in which cryptic acceptor
sites in the first 15 nt of exon 5 are used. After trans-
fection of a fragment of the mutant allele into COS-7
cells, when we attempted to replicate the effects of the
mutation, we found, to our surprise, that only one prod-
uct was produced—one of the minor products seen in
cells from the affected individual, in which a cryptic site
in exon 5 is used. These findings suggest that additional
mRNA sequences are an important factor in the deter-
mination of the outcome of the mutation, since the se-
quences of introns 4 and 7 had been truncated for the
purposes of the COS-7 cell transfection.
In cells from the patient, in some transcripts, intron 5
was removed rapidly, but, in other transcripts, intron 6
was removed prior to intron 5. Transcripts of the mutant
allele from which intron 5 but not introns 4 and 6 had
Figure 7 Secreted pro-a1(V)–derived chains incorporated into the extracellular matrix of control and patient cells. Bands on immunoblots
were detected with polyclonal antibodies that were directed against sequences in the variable subdomain of the pro-a1(V) N-propeptide. A,Matrix
showing multimeric and monomeric forms of pro-a1(V)–derived chains. Braces ({) indicate the multimeric forms. B, Close-up of a portion of a
longer exposure of the immunoblot seen in panel A. C, Peptides liberated from matrix by treatment with bacterial collagenase. D, Representation
of the 5′ end of COL5A1, the intron-exon structure, the predicted protein domains encoded by each exon, and the peptides derived from the
matrix after cleavage with bacterial collagenase, which degrades the major collagenous domain (COL). The antibody-recognition domain (*),
the site of BMP-1 cleavage, the PARP and variable domains, and the signal peptide (SP) are shown. Although the peptides have predicted
molecular masses that are below the apparent molecular weights, these differences are probably due to N-linked glycosylation at sites in the
PARP and variable subdomains.
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Figure 8 Electron micrograph of collagen fibrils synthesized in culture by cells from a control individual (left) and from the patient (right).
Fibrils formed by the control cells are small and compact with smooth contours and normal periodic staining. Fibrils from the patient cells
have a complex architecture with irregular, jagged contours and longitudinal twists.
been removed accumulated in the nucleus, providing a
substrate for the skipping of the fused 5-6 exon in one
splicing event. Additional products accumulated inwhich
introns 5 and 6 were removed such that neither exon 5
nor the combination of exons 5 and 6 could be removed.
These instead provided the substrate in which the cryptic
splice-acceptor sites in exon 5 could be used (see fig. 6).
Because the internal intron (intron 5, in this case) was
removed rapidly, the fused 5-6 exon could be removed
rapidly, which could explain why the product of the two-
exon skip was the major outcome of the mutation. As
generally described, exon- and intron-definition models
do not predict the proportion of different outcomes that
result from a single mutation. When the order of intron
removal is considered, it is apparent that the different
products derive from different pathways, in proportion
to the molecules that traverse each pathway.
Our studies suggest that, if splice-site mutations lead
to two-exon skipping, then the exons chosen will differ
depending on whether the mutation is at an acceptor site
or a donor site. In the example here, the acceptor-site
mutation leads to the removal of the two downstream
exons, because those exons can be fused to a “single”
exon while the next downstream intron and the muta-
tion-bearing intron remain in the transcript. If, however,
the mutation is at a donor site, then the removal of the
upstream intron creates a “single” exon that, if the next
upstream intron is retained, allows the skipping of the
two exons upstream from the mutation site. This out-
come is seen with a splice-donor site in the NF1 gene
(Fang et al. 2001). Other studies of naturally occurring
splice-site mutations in the human HPRT gene (O’Neill
et al. 1998) and of induced mutations in the dhfr gene
in Chinese hamster ovary cells (Carothers et al. 1993)
have identified examples of two-exon skips that often
conform to this model. In instances that do not, the loss
of the second exon of the pair re-creates an in-frame
product that is then stable. In these instances, it is often
difficult to determine the extent to which the product of
the two-exon skip represents a major splicing pathway
or is simply the only product that is in-frame and thus
is not subject to nonsense-mediated decay. Thus, whereas
pathways in which the intervening intron is removed first
may be the explanation for those events in which the
skipping of either exon would provide a stable product,
other mechanisms may be involved in other situations.
Relationships between COL5A1 mutations and the
EDS phenotype are not entirely clear. In the present in-
stance, unlike a number of other reported cases of clas-
sical EDS, the phenotype does not result from haploin-
sufficiency, as pro-a1(V)–derived chains encoded by the
mutant allele are efficiently incorporated into the extra-
cellular matrix. Rather, the mutation results in pro-a1(V)
chains with an altered N-propeptide (most of which are
missing the BMP-1 cleavage site encoded in exon 5) that
appears to interfere with normal processing.
Dermal collagen fibrils are abnormal in several forms
of EDS (Holbrook and Byers 1989). The most dramatic
alterations occur in EDS type VIIC, or dermatosparax-
is—in which deficiency of the enzyme procollagen N-
proteinase leaves the N-propeptides of type I procol-
lagen intact and sheets, rather than cylindrical fibrils,
form (Smith et al. 1992). In EDS types VIIA and
VIIB—in which part or all of the telopeptide sequences
encoded by exon 6 of COL1A1 or COL1A2, respec-
tively, are deleted from the protein—fibril formation is
disrupted, but not as dramatically (Cole et al. 1987;
Byers et al. 1997). Most individuals with EDS types I
and II also have abnormal fibrils in skin (Holbrook and
Byers 1989; Hausser and Anton-Lamprecht 1994). Fi-
bril diameter is generally larger than normal, fibril bor-
ders are irregular, and composite fibrils are common.
These aberrations occur in individuals who have alter-
ations in the triple-helical domains of the type V col-
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lagen genes (Nicholls et al. 1996) and also in individuals
in whom the mRNA from one allele of the COL5A1
gene is extremely unstable (Schwarze et al. 2000). In
culture, cells from the individual studied here produced
strikingly abnormal fibrils. Presumably, retention of the
additional amino-terminal sequences on some pro-
a1(V)–derived molecules—and/or derangement, due to
loss of cysteines involved in intramolecular disulfide
bonding, in the tertiary configuration of the N-propep-
tides—interferes with normal fibrillogenesis. Retained
N-terminal variable subdomain sequences of mature
a1(V) chains protrude beyond the surface of type I/type
V heterotypic collagen fibrils and are hypothesized to
play a role in the regulation of their diameters (Linsen-
mayer et al. 1993). Our results present in vivo evidence
that the pro-a1(V) globular N-terminal sequences play
an important role in the regulation of collagen fibril
architecture. Moreover, the bizarre architecture of col-
lagen fibrils that result from the N-propeptide mutation
in the present report suggests roles for pro-a1(V) N-
terminal sequences that lie beyond their postulated role
in the prevention of addition, to heterotypic fibril sur-
faces via steric hindrance, of type I collagen monomers
(Linsenmayer et al. 1993). The extent of derangement
of the patient’s collagen fibrils here suggests the presence
of additional mechanisms that have yet to be under-
stood. Rare individuals such as this patient who have
mutations that affect coding sequences and that have
either unknown or only postulated roles in fibril for-
mation provide those occasional glimpses into the bi-
ological prerequisites for collagen fibrillogenesis.
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